NYSE$ALUR
Allurion Technologies Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Results for the first quarter ended March 31, 2025
Allurion reported its first quarter 2025 financial results, showing reduced operating expenses and net operating loss, an improved gross margin, and progress toward FDA approval, while maintaining its full-year revenue guidance.
- Reported first quarter 2025 revenue of $5.6 million.
- Achieved a gross margin of 75% in Q1 2025, compared to 73% in the prior year.
- Reduced total operating expenses by 37% year-over-year to $11.4 million.
- Reduced net operating loss by 36% year-over-year to $7.3 million.
Headline financials
Revenue & EPS history
Allurion · Revenue · Quarterly
$5.58M
Forward guidance
For 2025, Allurion expects revenue of approximately $30 million and a reduction of approximately 50% in operating expenses compared to 2024, aiming for increased efficiency and progress towards profitability. The company is also on track to complete its FDA PMA submission by the end of June 2025 and plans to start enrolling a prospective trial on the combination of the Allurion Program with low-dose GLP-1 medications this year.
Tailwinds
- Maintaining 2025 revenue guidance at approximately $30 million.
- Anticipating a significant reduction in operating expenses (approx. 50% vs 2024).
- Expect to complete FDA PMA submission by the end of June 2025.
- Planning to start enrolling a prospective trial on the combination of the Allurion Program with low-dose GLP-1 medications in 2025.
- Focus on "Metabolically Healthy Weight Loss" with GLP-1 combination seen as a potential growth area.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
+1.5%
Avg return
Earnings day
+0.8%
Avg return
5 days after
+63.8%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+47.1%
Q4 2025
Best reaction
-43.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +25.0% | +25.1% | +1467.3% | |
| Q4 2025 | +47.1% | +35.3% | +47.1% | |
| Q3 2025 | +1.4% | -6.0% | +12.1% | |
| Q2 2025 | +0.8% | -8.1% | -16.3% | |
| Q1 2025 | +25.1% | +29.7% | +5.1% | |
| Q4 2024 | +0.3% | +3.2% | -22.8% | |
| Q3 2024 | -43.7% | -46.2% | -51.3% | |
| Q2 2024 | -12.7% | -17.0% | -20.8% | |
| Q1 2024 | -1.0% | -8.8% | -28.4% | |
| Q4 2023 | -11.9% | -11.0% | -5.2% | |
| Q3 2022 | +2.4% | +0.7% | -18.7% | |
| Q3 2023 | +6.7% | +2.4% | -15.9% | |
| Q2 2022 | -2.3% | +3.8% | -3.6% | |
| Q1 2023 | -2.3% | +3.8% | -3.6% | |
| Q2 2023 | -2.3% | +3.8% | -3.6% | |
| Q4 2022 | -2.3% | +3.8% | -3.6% | |
| Q1 2022 | +0.0% | +0.2% | +0.3% | |
| Q4 2021 | +0.1% | +0.3% | -0.1% | |
| Q3 2021 | -0.2% | +0.0% | +0.0% | |
| Q2 2021 | -0.1% | -0.5% | -1.3% | |
| Q1 2021 | +0.9% | +1.0% | +2.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro